# Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

> **NCT02671097** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 30 (actual)

## Conditions studied

- Healthy Volunteers
- Pharmacokinetics
- Drug Interaction

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** BAY1841788 (ODM-201)

## Key facts

- **NCT ID:** NCT02671097
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-05
- **Final completion:** 2016-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02671097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02671097, "Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02671097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*